Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
LRPPRC
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "LRPPRC" in MCE Product Catalog:
Cat. No.: HY-RS07804
Target:
Research Areas:
LRPPRC Human Pre-designed siRNA Set A contains three designed siRNAs for LRPPRC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS20563
Target:
Research Areas:
Lrpprc Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrpprc gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-168519
CAS No.: 3055766-74-7
STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM. .
Cat. No.: HY-187350
Research Areas:
LRPPRC-IN-1 is a LRPPRC inhibitor. LRPPRC-IN-1 exerts dual effects of inhibiting LRPPRC activity and inducing its degradation by binding to the RNA-binding domain of LRPPRC. LRPPRC-IN-1 downregulates the expression of mitochondrial OXPHOS complex subunits and ATP synthase, inhibits oxidative phosphorylation, reduces ATP production, suppresses the proliferation and colony formation of various cancer cells, and inhibits tumor growth in vivo. LRPPRC-IN-1 can be used in studies related to lung cancer, pancreatic cancer, breast cancer, esophageal cancer, colorectal cancer, lymphoma, melanoma, cervical cancer, ovarian cancer, and prostate cancer .
Cat. No.: HY-RS27072
Target:
Research Areas:
Lrpprc Rat Pre-designed siRNA Set A contains three designed siRNAs for Lrpprc gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-181098
CAS No.: 3060515-85-4
Research Areas:
FKA-9i is an orally active anticancer agent. FKA-9i directly binds to and promotes the degradation of oncoproteins LRPPRC (kd: 7.387 μM), YBX1 (kd: 16.52 μM) and RPN1 (kd: 26.82 μM). FKA-9i inhibits the MAPK signaling pathway and mitochondrial oxidative phosphorylation. FKA-9i also induces cancer cell cycle arrest, apoptosis, mitochondrial dysfunction and ROS accumulation. FKA-9i can be used in the research of tumors such as gastric cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
